Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    GU10-147
Show Display Options
Rank Status Study
1 Recruiting First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Conditions: Transitional Cell Carcinoma;   Bladder Carcinoma;   Urothelial Carcinoma
Interventions: Drug: Everolimus;   Drug: Paclitaxel
2 Terminated
Has Results
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib;   Drug: imatinib (Gleevec/ Glivec)
3 Recruiting Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting
Conditions: Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion;   Wet Age Related Macular Degeneration;   Diabetic Macular Edema;   Retinal Vein Occlusion
Interventions: Drug: Ranibizumab;   Other: Ranibizumab

Indicates status has not been verified in more than two years